Top 5 Stocks to Buy Now
→ The Treasury just bought its own debt (From Golden Portfolio) (Ad)tc pixel Free NCEL Stock Alerts

NLS Pharmaceutics (NCEL) Competitors

NLS Pharmaceutics logo
$3.54 +0.05 (+1.43%)
As of 06/23/2026 03:58 PM Eastern
Compare

NCEL vs. UPXI, BYSI, CING, BHST, and ACRV

Should you buy NLS Pharmaceutics stock or one of its competitors? MarketBeat compares NLS Pharmaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NLS Pharmaceutics include Upexi (UPXI), BeyondSpring (BYSI), Cingulate (CING), BioHarvest Sciences (BHST), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry.

How does NLS Pharmaceutics compare to Upexi?

NLS Pharmaceutics (NASDAQ:NCEL) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Upexi has a consensus target price of $8.33, suggesting a potential upside of 898.00%. Given Upexi's stronger consensus rating and higher possible upside, analysts clearly believe Upexi is more favorable than NLS Pharmaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Upexi
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

NLS Pharmaceutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Upexi has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market.

5.7% of Upexi shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 9.0% of Upexi shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Upexi had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 2 mentions for Upexi and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Upexi'saverage media sentiment score.

Company Overall Sentiment
NLS Pharmaceutics Neutral
Upexi Neutral

NLS Pharmaceutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. NLS Pharmaceutics' return on equity of 0.00% beat Upexi's return on equity.

Company Net Margins Return on Equity Return on Assets
NLS PharmaceuticsN/A N/A N/A
Upexi -874.00%-66.70%-19.56%

NLS Pharmaceutics has higher earnings, but lower revenue than Upexi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A
Upexi$15.81M3.71-$13.68M-$0.62N/A

Summary

Upexi beats NLS Pharmaceutics on 7 of the 13 factors compared between the two stocks.

How does NLS Pharmaceutics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

BeyondSpring has higher revenue and earnings than NLS Pharmaceutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpring$1.75M37.83-$1.01M-$0.14N/A
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeyondSpring
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
BeyondSpringN/A N/A -14.00%
NLS Pharmaceutics N/A N/A N/A

BeyondSpring has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

40.3% of BeyondSpring shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled NLS Pharmaceutics'average media sentiment score.

Company Overall Sentiment
BeyondSpring Neutral
NLS Pharmaceutics Neutral

Summary

BeyondSpring beats NLS Pharmaceutics on 4 of the 6 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Cingulate?

Cingulate (NASDAQ:CING) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

NLS Pharmaceutics' return on equity of 0.00% beat Cingulate's return on equity.

Company Net Margins Return on Equity Return on Assets
CingulateN/A -365.15% -158.55%
NLS Pharmaceutics N/A N/A N/A

41.3% of Cingulate shares are held by institutional investors. 5.3% of Cingulate shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/A-$22.45M-$4.23N/A
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A

Cingulate has a beta of -0.85, meaning that its share price is 185% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

In the previous week, Cingulate had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for NLS Pharmaceutics. Cingulate's average media sentiment score of 0.84 beat NLS Pharmaceutics' score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Positive
NLS Pharmaceutics Neutral

Cingulate currently has a consensus price target of $27.33, suggesting a potential upside of 465.91%. Given Cingulate's stronger consensus rating and higher possible upside, research analysts clearly believe Cingulate is more favorable than NLS Pharmaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cingulate
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Cingulate beats NLS Pharmaceutics on 6 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to BioHarvest Sciences?

NLS Pharmaceutics (NASDAQ:NCEL) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

NLS Pharmaceutics has higher earnings, but lower revenue than BioHarvest Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A
BioHarvest Sciences$34.51M1.76-$11.14M-$0.59N/A

NLS Pharmaceutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. NLS Pharmaceutics' return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
NLS PharmaceuticsN/A N/A N/A
BioHarvest Sciences -32.54%-76.03%-25.30%

BioHarvest Sciences has a consensus target price of $10.00, suggesting a potential upside of 222.58%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than NLS Pharmaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

NLS Pharmaceutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

In the previous week, BioHarvest Sciences had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for BioHarvest Sciences and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled BioHarvest Sciences'average media sentiment score.

Company Overall Sentiment
NLS Pharmaceutics Neutral
BioHarvest Sciences Neutral

Summary

NLS Pharmaceutics and BioHarvest Sciences tied by winning 5 of the 10 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Acrivon Therapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Acrivon Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Acrivon Therapeutics and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Acrivon Therapeutics'average media sentiment score.

Company Overall Sentiment
NLS Pharmaceutics Neutral
Acrivon Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A
Acrivon TherapeuticsN/AN/A-$77.90M-$2.00N/A

Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 615.75%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than NLS Pharmaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

NLS Pharmaceutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NLS PharmaceuticsN/A N/A N/A
Acrivon Therapeutics N/A -64.43%-57.08%

Summary

Acrivon Therapeutics beats NLS Pharmaceutics on 6 of the 10 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCEL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCEL vs. The Competition

Export
MetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$18.66M$2.96B$6.44B$12.30B
Dividend YieldN/A1.80%2.69%5.83%
P/E RatioN/A18.4324.6623.99
Price / SalesN/A341.56531.91108.06
Price / CashN/A56.3144.8254.51
Price / Book2.234.1110.816.50
Net Income-$8.30M$64.45M$3.56B$336.88M
7 Day Performance12.38%1.41%0.93%-0.16%
1 Month Performance12.03%1.04%0.35%0.76%
1 Year Performance-84.41%23.88%29.69%28.49%

NLS Pharmaceutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCEL
NLS Pharmaceutics
0.5864 of 5 stars		$3.54
+1.4%		N/A-84.8%$18.66MN/AN/A6
UPXI
Upexi
1.9942 of 5 stars		$0.97
+1.4%		$8.33
+763.6%		-91.7%$68.08M$15.81MN/A130
BYSI
BeyondSpring
0.0418 of 5 stars		$1.63
+1.9%		N/A-41.2%$67.40MN/AN/A80
CING
Cingulate
3.2925 of 5 stars		$5.01
+5.7%		$27.33
+445.4%		+19.6%$67.28MN/AN/A20
BHST
BioHarvest Sciences
2.3697 of 5 stars		$3.36
+1.4%		$10.00
+198.0%		-54.6%$65.85M$34.51MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
Four winners over 400%. Here's #5
CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...
Golden Portfolio | Sponsoredtc pixel
25-Cent Gold Explorer Set to Drill Top Canadian Mineral Belt
With gold racing toward US$5,000 an ounce, one sub-$0.25 explorer is launching a fully funded drill campaign o...
Resource Stock Digest | Sponsoredtc pixel
My feud with Zohran Mamdani
Nearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...
Stansberry Research | Sponsoredtc pixel
Big Oil knew about this for 50 years
In the 1970s, Chevron, Unocal, and Texaco all drilled the same energy source - and walked away to protect oil ...
Behind the Markets | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel